2,333
Participants
Start Date
November 30, 2013
Primary Completion Date
August 31, 2014
Study Completion Date
August 31, 2014
QIVc
Novartis Investigational Quadrivalent Vaccine
TIV1c
Licensed Influenza Vaccine
TIV2c
Novartis Investigational Vaccine
Binghamton
Upper Saint Clair
Hermitage
Erie
Erie
Sellersville
Burke
Charlottesville
Wilmington
Charleston
Mt. Pleasant
Anderson
Marietta
Woodstock
Atlanta
Lake Mary
Melbourne
Opa-locka
Miami Beach
Boca Raton
Pinellas Park
Huntsville
Mobile
Lebanon
Nashville
Bristol
Jefferson City
Louisville
Lexington
Cleveland
Cleveland
Akron
Cincinnati
Dayton
Dayton
Kettering
Mishawaka
Council Bluffs
Peoria
St Louis
Kansas City
Wichita
Newton
Wichita
Bellevue
Fremont
Omaha
Omaha
Metairie
Jonesboro
Harrisburg
Oklahoma City
Oklahoma City
Tulsa
Dallas
Fort Worth
Fort Worth
San Angelo
San Antonio
Round Rock
Austin
Thornton
Denver
Denver
Colorado Springs
Boise
Draper
Layton
West Jordan
South Jordan
Salt Lake City
Salt Lake City
Salt Lake City
Mesa
Mesa
Chandler
Las Vegas
Downey
Paramount
West Covina
Anaheim
Anaheim
Garden Grove
San Francisco
Modesto
Santa Rosa
Sacramento
San Diego
Lead Sponsor
Novartis Vaccines
INDUSTRY